Sumida Shawn, Lesley Maggie R, Hanna Marie N, Murphy Jamie D, Kumar Kanupriya, Wu Christopher L
Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University and School of Medicine, Baltimore, Maryland, USA.
J Opioid Manag. 2009 Sep-Oct;5(5):301-5. doi: 10.5055/jom.2009.0030.
Extended-release epidural morphine (EREM) is a single-dose, extended-release epidural morphine formulation intended to provide postoperative pain relief over a 48-hour period. There have been a few randomized controlled trials investigating the use and safety of EREM versus intravenous patient-controlled analgesia with opioids (IV-PCA); however, the adverse event of respiratory depression of this treatment is unclear. The authors have undertaken a meta-analysis to examine this issue.
A systematic literature search of the National Library of Medicine's PubMed database was conducted for terms related to EREM. Only randomized controlled trials, in the English language, assessing the rates of respiratory depression of EREM to IV-PCA were included for analysis. Data on pertinent study characteristics and relevant outcomes were extracted from accepted articles. Meta-analysis was performed using the Review Manager 4.2.7 (The Cochrane Collaboration, 2004). A random effects model was used.
The authors' literature search yielded three articles which met all inclusion criteria. All studied doses of EREM were evaluated. Pooled estimates (odds ratio) were made for rates of adverse events of respiratory depression. Use of EREM was associated with significantly higher odds of respiratory depression compared to IV-PCA (odds ratio = 5.74; 95% confidence interval: 1.08, 30.54, p = 0.04). Even when examining only Food and Drug Administration approved dosages for EREM, the use of EREM was associated with significantly higher odds of respiratory depression when compared with IV-PCA (odds ratio = 5.80; 95% confidence interval: 1.05, 31.93, p = 0.04).
Although perioperative single-dose epidural EREM (versus IV-PCA) was effective for postoperative pain relief for up to 48 hours, it is associated with significantly higher odds of respiratory depression. Further examination of the issue of respiratory depression of epidural EREM may be warranted.
缓释硬膜外吗啡(EREM)是一种单剂量的缓释硬膜外吗啡制剂,旨在提供长达48小时的术后疼痛缓解。已有一些随机对照试验研究了EREM与静脉自控阿片类镇痛(IV-PCA)的使用及安全性;然而,这种治疗的呼吸抑制不良事件尚不清楚。作者进行了一项荟萃分析来研究这个问题。
对美国国立医学图书馆的PubMed数据库进行系统的文献检索,查找与EREM相关的术语。仅纳入以英文发表的、评估EREM与IV-PCA呼吸抑制发生率的随机对照试验进行分析。从入选文章中提取有关研究特征和相关结果的数据。使用Review Manager 4.2.7(Cochrane协作网,2004年)进行荟萃分析。采用随机效应模型。
作者的文献检索得到3篇符合所有纳入标准的文章。对所有研究的EREM剂量进行了评估。对呼吸抑制不良事件的发生率进行了合并估计(比值比)。与IV-PCA相比,使用EREM发生呼吸抑制的几率显著更高(比值比 = 5.74;95%置信区间:1.08,30.54,p = 0.04)。即使仅检查美国食品药品监督管理局批准的EREM剂量,与IV-PCA相比,使用EREM发生呼吸抑制的几率仍显著更高(比值比 = 5.80;95%置信区间:1.05,31.93,p = 0.04)。
尽管围手术期单剂量硬膜外EREM(与IV-PCA相比)在长达48小时的术后疼痛缓解方面有效,但它与显著更高的呼吸抑制几率相关。可能有必要进一步研究硬膜外EREM的呼吸抑制问题。